Niagen Bioscience (NAGE) Free Cash Flow Growth (3y) (2016 - 2026)
Niagen Bioscience (NAGE) Free Cash Flow Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Niagen Bioscience | 258.53 Mn | 191.98 Mn | 19.98 Mn | -34.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.40% |
| Dec 31, 2025 | 60.65% |
| Sep 30, 2025 | 44.05% |
| Jun 30, 2025 | 32.34% |
| Mar 31, 2025 | 45.73% |
| Dec 31, 2024 | 55.17% |
| Sep 30, 2024 | 37.34% |
| Jun 30, 2024 | 67.78% |
| Mar 31, 2024 | 27.13% |
| Dec 31, 2023 | 208.99% |
| Sep 30, 2023 | 28.12% |
| Jun 30, 2023 | 58.61% |
| Mar 31, 2023 | 36.32% |
| Dec 31, 2022 | 28.30% |
| Sep 30, 2022 | 22.11% |
| Jun 30, 2022 | 25.02% |
| Mar 31, 2022 | -29.86% |
| Dec 31, 2021 | 1.33% |
| Sep 30, 2021 | -3.93% |
| Jun 30, 2021 | -1.01% |